☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

For the quarter ended March 2025, EyePoint Pharmaceuticals (EYPT) reported revenue of $24.45 million, up 109.4% over the same period last year. EPS came in at -$0.65, compared to -$0.55 in the year-ago quarter.The reported revenue represents a surprise of +345.17% over the Zacks Consensus Estimate of $5.49 million. With the consensus EPS estimate being -$0.65, the company has not delivered EPS surprise.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...

EyePoint Pharmaceuticals (EYPT) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Good morning. My name is Towanda, and I'll be your conference operator today. At this time, I would like to welcome everyone to the ICON First Quarter twenty twenty five Financial Results and Recent Corporate Development Conference Call. There will be a question and answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the company's risk request. I would ...

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non- recurring items. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.41 per share when it actually produced a loss of $0.64, delivering a surprise of -56.10%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates ...

Exhibit 99.1 EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2 ...

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2025, and highlighted recent corporate developments. "We continue to make outstanding progress with our two Phase 3 pivotal trials for DURAVYU in wet age- related macular degeneration (AMD) and have a ...

WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio ...

Investors: Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The proven Durasert drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, ...

Financial Performance - Total revenues decreased by $2.7 million, or 6%, to $43.3 million in 2024 compared to $46.0 million in 2023[438]. - Product sales, net decreased by $11.1 million, or 78%, to $3.2 million in 2024 due to the licensing agreement with ANI[439]. - License and collaboration agreement revenues increased by $7.7 million, or 25%, to $38.5 million in 2024 compared to $30.8 million in 2023[441]. - Royalty income increased by $0.6 million, or 63%, to $1.6 million in 2024, primarily from increased royalties from Ocumension Therapeutics[442]. - For the year ended December 31, 2024, the net loss was $130.9 million, an increase of $60.1 million compared to a net loss of $70.8 million in 2023[459]. - Operating cash outflows for 2024 totaled $126.2 million, significantly down from an inflow of $1.9 million in 2023, reflecting a change of $128.1 million[459][460]. - Net cash used in investing activities for 2024 was $219.4 million, a substantial increase from $3.3 million in 2023, indicating a change of $216.0 million[459][461]. - Net cash provided by financing activities for 2024 was $164.0 million, a decrease of $23.0 million from $187.1 million in 2023[462]. - Changes in working capital for 2024 included $30.6 million of deferred revenue related to licensing YUTIQ® product rights, compared to $44.5 million in 2023[459][460]. - Non-cash expenses in 2024 included $36.7 million of stock-based compensation, up from $12.1 million in 2023[459][460]. - Interest income increased by $8.1 million, or 117%, to $15.1 million in 2024, attributed to higher cash invested in marketable securities[447]. Clinical Development - DURAVYU™, the lead product candidate, is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and Phase 2 trials for diabetic macular edema (DME)[416]. - The Phase 2 DAVIO 2 clinical trial of DURAVYU™ showed positive twelve-month safety and efficacy data, confirming its potential in treating wet AMD[420]. - The VERONA trial for DURAVYU™ in DME patients completed enrollment with 27 patients, with topline data expected in Q1 2025[420]. - The Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ are designed for potential global regulatory success, with rapid enrollment anticipated due to robust DAVIO 2 data[420]. - DURAVYU™ demonstrated a +7.1 letter gain in BCVA and a 76-micron reduction in CST at week 24 in the ongoing Phase 2 VERONA trial[421]. - The company is focused on the clinical development of product candidates, including DURAVYU™ and EYP-2301, with expectations regarding their timing and outcomes[461]. Manufacturing and Operations - The company announced the grand opening of a 40,000 square foot cGMP compliant manufacturing facility in Northbridge, MA, to support global manufacturing[418]. - The company plans to cease manufacturing YUTIQ® for the U.S. market effective June 1, 2025, following the acquisition of Alimera by ANI Pharmaceuticals[425]. - The company is assessing the costs and timing for implementing corrective actions required by the FDA's Warning Letter[461]. Management and Personnel - The company appointed Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer and Fred Hassan to the Board of Directors in 2024[417]. Financial Position and Future Outlook - As of December 31, 2024, the company had cash and investments of $370.9 million, expected to fund operations into 2027[455]. - The company anticipates potential challenges in securing additional funding for future operations and clinical trials[458]. - The company is evaluating its capital needs and the potential for raising capital in the future[461]. - The company does not have any off-balance sheet arrangements that could materially affect its financial condition[462].

EyePoint Pharmaceuticals (EYPT) Q4 2024 Earnings Call March 05, 2025 05:42 PM ET Company Participants George Elston - Executive VP & CFOJay Duker - President, CEO & DirectorRamiro Ribeiro - Chief Medical OfficerYigal Nochomovitz - DirectorKambiz Yazdi - Vice President - Equity ResearchJennifer Kim - Equity Research DirectorGraig Suvannavejh - Managing DirectorDebanjana Chatterjee - DirectorGreg Harrison - Director-BiotechnologyYi Chen - Managing Director, Equity Research Conference Call Participants Tessa R ...